세계의 아토피 피부염 시장 보고서(2025년)
Atopic Dermatitis Global Market Report 2025
상품코드 : 1821613
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

아토피 피부염 시장의 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 170억 8,000만 달러로 성장할 전망이며 CAGR은 14.7%에 다다를 전망입니다. 예측기간의 성장은 생물학적 요법의 진보, 면역조절제 및 저분자제, 소아에 특화된 치료, 유전자 치료 및 정밀의료, 디지털 헬스 통합에 기인할 것으로 예측됩니다. 예측기간 중 주요 동향으로는 외용약의 기술적 진보, 소아의료에 대한 주력, 환경 및 알러지원 관리, 정밀 진단 툴 등을 들 수 있습니다.

향후 5년간의 예측 성장률 14.7%는 이 시장의 과거 예측에서 0.4% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 덴마크와 프랑스에서 개발된 생물학적 치료제 및 치료용 보습제의 가격을 상승시켜 미국의 피부과 치료에 지장을 초래하여 염증이 장기화되고 전문 약국의 지출이 증가할 수 있습니다. 또한 상호관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

아토피 피부염의 유병률 증가는 아토피 피부염 시장의 큰 성장을 가속할 것으로 예측됩니다. 습진으로도 알려진 아토피 피부염은 건조와 가려움증을 특징으로 하는 피부질환입니다. 이 증상을 앓고 있는 사람의 수가 증가함에 따라 효과적인 진단과 치료 옵션에 대한 수요도 증가하고 있습니다. 예를 들어 영국의 출판사 옥스포드 아카데믹에 따르면 아토피 피부염은 세계적으로 매우 보급되어 있으며 2024년에는 세계 인구의 약 2.6%인 약 2억 400만 명에 영향을 미쳤다고 밝혔습니다. 이 인구에는 약 1억 100만 명의 성인과 1억 300만 명의 어린이가 포함됩니다. 따라서, 아토피 피부염의 보급이 아토피 피부염 시장의 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Atopic dermatitis is a chronic dermatological condition characterized by skin dryness and itching. This condition progresses over time and is not contagious through contact.

The main drug classes used to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory drugs that mimic cortisol and are employed in the treatment of various diseases, including rheumatological conditions, rheumatoid arthritis, lupus, and atopic dermatitis. These drugs can be administered through various modes, such as topical, injectable, and oral, and are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atopic dermatitis market size has grown rapidly in recent years. It will grow from $8.61 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, treatment options evolution, research and development.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $17.08 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to biologic therapies advancements, immunomodulators and small molecule drugs, pediatric-specific treatments, gene therapy and precision medicine, digital health integration. Major trends in the forecast period include technological advancements in topicals, pediatric ad care focus, environmental and allergen management, precision diagnosis tools.

The forecast of 14.7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. dermatology care by inflating prices of biologic treatments and therapeutic moisturizers developed in Denmark and France, resulting in prolonged flare-ups and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of atopic dermatitis is expected to drive significant growth in the atopic dermatitis market. Also known as eczema, atopic dermatitis is a skin condition characterized by dryness and itchiness. As the number of individuals affected by this condition increases, so does the demand for effective diagnosis and treatment options. For example, according to Oxford Academic, a UK-based publishing company, atopic dermatitis is highly prevalent worldwide, impacting around 2.6% of the global population, which translates to approximately 204 million people in 2024. This population includes about 101 million adults and 103 million children. Consequently, the growing incidence of atopic dermatitis is fueling the expansion of the atopic dermatitis market.

The growing demand for personalized medicine is anticipated to contribute significantly to the expansion of the atopic dermatitis market. Personalized medicine involves tailoring medical interventions, including drug therapies, to suit individual patient characteristics, such as genetics and molecular factors. This approach ensures more targeted and effective treatments while minimizing adverse effects. For example, as of October 2022, reports indicated a vast array of over 75,000 genetic testing products and 300 personalized medicines, underlining the surging demand for tailored therapeutic options. This trend is fueling the growth of the atopic dermatitis market by emphasizing more precise and patient-centric treatment approaches.

Innovations in product development are emerging as a pivotal trend within the atopic dermatitis market, with major companies introducing novel solutions to reinforce their market position. Notably, in June 2022, Regeneron Pharmaceuticals Inc., a prominent US-based biotechnology company, secured FDA approval for Dupixent (dupilumab). Dupixent is a medication designed for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. This groundbreaking drug works by inhibiting the signaling of two critical Type 2 inflammatory sources (IL-4 and IL-13), contributing to the development of various conditions such as eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma. The approval of Dupixent represents a significant advancement in pediatric atopic dermatitis treatment, promising more effective therapeutic options for young patients.

Major companies within the atopic dermatitis market are strategically pursuing product approvals to stimulate revenue growth within their industry. Product approvals signify the official endorsement granted by health regulatory bodies, affirming the safety and effectiveness of pharmaceuticals or treatments for managing inflammatory skin conditions like atopic dermatitis. Notably, in January 2022, AbbVie Inc., a prominent US-based pharmaceutical company, secured FDA approval for Rinvoq. Rinvoq, containing upadacitinib as its active component, belongs to the class of janus kinase (JAK) inhibitors, a targeted synthetic disease-modifying antirheumatic drug. This medication received approval for treating moderate-to-severe atopic dermatitis in both adults and children aged 12 years and above. Rinvoq serves as an alternative when other treatments, including biologic medicines or conventional medications, have been ineffective in managing the condition, or when their usage is not recommended. It is noteworthy that Rinvoq (upadacitinib) can be administered in conjunction with methotrexate or as monotherapy, thereby broadening treatment options for atopic dermatitis patients.

In September 2022, Arcutis Biotherapeutics, a prominent commercial-stage biopharmaceuticals firm headquartered in the United States, finalized the acquisition of Ducentis BioTherapeutics for an undisclosed sum. This strategic acquisition is envisioned to reinforce Arcutis Biotherapeutics' position within the medical dermatology sector while enhancing its capacity to address the unmet medical needs of patients dealing with dermatological conditions. Notably, Ducentis BioTherapeutics, a preclinical-stage biotechnology company also based in the US, specializes in the development of primary treatments targeting atopic dermatitis, aligning with Arcutis Biotherapeutics' commitment to advancing therapies for this skin disorder.

Major companies operating in the atopic dermatitis market are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

North America was the largest region in the atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atopic Dermatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for atopic dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The atopic dermatitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Atopic Dermatitis Market Characteristics

3. Atopic Dermatitis Market Trends And Strategies

4. Atopic Dermatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Atopic Dermatitis Growth Analysis And Strategic Analysis Framework

6. Atopic Dermatitis Market Segmentation

7. Atopic Dermatitis Market Regional And Country Analysis

8. Asia-Pacific Atopic Dermatitis Market

9. China Atopic Dermatitis Market

10. India Atopic Dermatitis Market

11. Japan Atopic Dermatitis Market

12. Australia Atopic Dermatitis Market

13. Indonesia Atopic Dermatitis Market

14. South Korea Atopic Dermatitis Market

15. Western Europe Atopic Dermatitis Market

16. UK Atopic Dermatitis Market

17. Germany Atopic Dermatitis Market

18. France Atopic Dermatitis Market

19. Italy Atopic Dermatitis Market

20. Spain Atopic Dermatitis Market

21. Eastern Europe Atopic Dermatitis Market

22. Russia Atopic Dermatitis Market

23. North America Atopic Dermatitis Market

24. USA Atopic Dermatitis Market

25. Canada Atopic Dermatitis Market

26. South America Atopic Dermatitis Market

27. Brazil Atopic Dermatitis Market

28. Middle East Atopic Dermatitis Market

29. Africa Atopic Dermatitis Market

30. Atopic Dermatitis Market Competitive Landscape And Company Profiles

31. Atopic Dermatitis Market Other Major And Innovative Companies

32. Global Atopic Dermatitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atopic Dermatitis Market

34. Recent Developments In The Atopic Dermatitis Market

35. Atopic Dermatitis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기